Peijia Medical
9996.HKSuzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile9996.HK · Stock Price
HKD 5.24-1.08 (-17.09%)
Market Cap: $453.7M
Historical price data
Overview
A leading Chinese medtech company developing innovative transcatheter heart valve and neurointerventional devices for structural heart disease and stroke.
CardiovascularNeurology
Technology Platform
Platform for designing and manufacturing minimally invasive transcatheter implant delivery systems and devices for structural heart repair and neurovascular intervention.
Opportunities
Significant growth from low penetration of TAVR and emerging mitral/tricuspid therapies in China, coupled with global expansion of neurointerventional products like the FDA-cleared DCwire guidewire.
Risk Factors
Faces intense competition in China's TAVR market from domestic (Venus Medtech, MicroPort) and global players (Edwards), and exposure to pricing pressure from China's volume-based procurement (VBP) policies.
Competitive Landscape
Competes directly with Venus Medtech and MicroPort in structural heart, and with MicroVention/Terumo, Wallaby/Stryker in neurointervention in China. Differentiation is based on a comprehensive 'heart-brain' portfolio, in-house R&D combined with strategic in-licensing, and a strong focus on physician education through its 'Yijia Academy'.